Skip to main content
DOUBLE MEDICAL TECHNOLOGY INC. logo

DOUBLE MEDICAL TECHNOLOGY INC. — Investor Relations & Filings

Ticker · 002901 ISIN · CNE1000032W7 LEI · 836800DECKX5CGFNMD42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 963 across all filing types
Latest filing 2022-04-15 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002901

About DOUBLE MEDICAL TECHNOLOGY INC.

https://www.double-medical.com

Double Medical Technology Inc. specializes in the development, manufacturing, and distribution of medical devices, with a primary focus on orthopedic solutions. The company's extensive product portfolio includes trauma fixation systems, spinal implants, joint prosthesis, and neurosurgical devices. Additionally, it provides specialized surgical instruments and advanced wound care products. Double Medical emphasizes research and innovation to deliver clinically effective solutions for complex musculoskeletal conditions. Its manufacturing processes adhere to international quality standards, ensuring the reliability of its implants and instruments used in hospitals and surgical centers worldwide. The company serves a global market, providing comprehensive support for orthopedic surgeons through its diverse range of reconstructive and regenerative medical technologies.

Recent filings

Filing Released Lang Actions
关于以募集资金置换预先投入募投项目自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement by a company regarding the use of raised funds to replace self-raised funds previously invested in projects. It includes details about the fundraising approval, amounts raised, project investment plans, board and supervisory approvals, independent director opinions, auditor verification, and sponsor institution review. The document is relatively short (3392 characters) and primarily serves as a formal disclosure of a financing update related to the company's capital structure and use of proceeds. It does not contain comprehensive financial statements or detailed financial performance data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a report publication announcement since it contains substantive content about the financing and fund usage. The content fits best under Capital/Financing Update (CAP) as it details fundraising, use of proceeds, and related approvals.
2022-04-15 Chinese
关于控股子公司开立募集资金专户的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the opening of a special account for raised funds by a controlling subsidiary. It details the approval of a non-public stock issuance, the amount raised, and the management of these funds, including the establishment of a dedicated account for the use of these funds. The document references regulatory approvals and previous announcements but does not contain financial statements or detailed financial performance data. It is primarily an update on fundraising and capital management activities, specifically about the use and storage of raised funds. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short and focused on fundraising details, not a full report or audit.
2022-04-15 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 23rd meeting of the company's second board of directors. It includes voting results on various agenda items such as approval of the 2022 Q1 report, feasibility analysis report, and funding replacement plans. The document references other detailed reports and announcements published separately on April 16, 2022, but itself does not contain the full financial data or detailed reports. The document is short (1434 characters) and serves as a meeting resolution announcement rather than the full report. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting decisions and approvals.
2022-04-15 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 21st meeting of the second Supervisory Board of Dabao Medical Technology Co., Ltd. It includes approval of the 2022 first quarter report and a proposal regarding the use of raised funds to replace self-raised funds for investment projects. The document states that the detailed 2022 first quarter report and the announcement about the fund replacement are published elsewhere and provides links to those reports. The document itself does not contain the full financial statements or substantive financial data but rather summarizes meeting decisions and refers to other filings for the full reports. The document length is short (1251 characters), consistent with an announcement rather than a full report. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full quarterly report or detailed financial data itself.
2022-04-15 Chinese
中信证券股份有限公司关于大博医疗科技股份有限公司以募集资金置换预先投入募投项目自筹资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of raised funds by Dabao Medical Technology Co., Ltd. to replace self-raised funds previously invested in projects. It references regulatory approvals, board and supervisory meetings, independent director opinions, and auditor verification reports. The content focuses on the compliance and approval process related to the use of capital raised through a non-public stock issuance. It is not a full financial report, earnings release, or presentation, but rather a formal verification and compliance opinion related to capital use and fundraising activities. This fits best under the category of Capital/Financing Update (CAP), as it deals with fundraising, capital allocation, and related approvals.
2022-04-15 Chinese
独立董事关于公司第二届董事会第二十三次会议审议事项的独立意见
Board/Management Information Classification · 85% confidence The document is a statement of independent directors' opinions regarding a specific board meeting agenda item about the use of raised funds to replace self-raised funds for investment projects. It references regulatory guidelines and the company's independent director system. The document is short (499 characters) and does not contain financial statements or detailed financial data. It is an opinion related to a board meeting but does not announce changes in board members or senior management. It is not a full report, earnings release, or regulatory filing. Given the nature of the document as an independent directors' opinion on a board meeting matter, it fits best under Board/Management Information (MANG).
2022-04-15 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.